Gamma Biosciences, a global life sciences company focused on advanced therapies, announced its portfolio company BioMagnetic Solutions (BMS) has signed a lease with GLP Development to build a cGMP-grade production facility in Innovation Park at Penn State. The site is expected to be fully operational in mid-2022 with more than 13,000 sq.-ft. of purpose-built office, laboratory, and cGMP manufacturing space. ISO 13485 and ISO 9001:2015 certifications have also been achieved to ensure the highest quality standards.
 
BioMagnetic Solutions is a next-generation cell selection and bioseparation technology company that develops advanced ferrofluid-based immunomagnetic cell selection systems. Founded in 2011 by Dr. Paul Liberti and Ted Liberti in State College, PA, the company has remained focused on developing proprietary nanoscale ferrofluids for high-performance cell selection and other bioseparation applications from research, to clinical development and commercial scale. In the new space, the team will work to support full commercialization of its proprietary selection technology platform.
 
“BMS began operations in the State College, Pennsylvania area, and when we originally signed our investment deal, we knew that we would want to continue growing in the state,” said Phil Vanek, CTO at Gamma Biosciences. “When we connected with the Innovation Park and the Center of Excellence in Industrial Biotechnology teams at Penn State, we knew we had found the right location to work on developing this game-changing technology while also contributing to this thriving ecosystem to support education and innovation.”
 
The state-of-the-art facility will house up to 30 technical, operational, and commercial personnel to support the launch of both Research Use and Clinical versions of the BioMagnetic Solutions cell separation platform. The product launch is expected in 1Q22.